ClinicalTrials.gg

Program

ravagalimab

Also written as “Ravagalimab”, “Ravagalimab 600 mg” and “Ravagalimab 300 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Colitis, Ulcerative · Sjogren's Syndrome, led by AbbVie.

Furthest: phase 2, since Oct 2, 20184 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie41 open or runningphase 2since Oct 2, 2018Oct 2, 2018Feb 2027phase 2 · NCT06972446

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 2, 2018First study: phase 2 study in Colitis, UlcerativeFirst studyNCT03695185 · 42 enrolled · United States, Canada, France and more
  2. Feb 6, 2020Phase 2 study in Sjogren's SyndromeNCT05217472 · Netherlands
  3. May 3, 2024Phase 1 study in Healthy VolunteersNCT06402513 · 12 enrolled · United States
  4. May 7, 2025Phase 2 study in Arthritis, RheumatoidNCT06972446 · 180 planned · United States, Canada, Czechia and more

Ahead

  1. Feb 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT06972446

TargetBeta

CD40LG →read by rule
“CD40 ligand antagonist”ChEMBL 37, by rule

Other programs on CD40LG

ProgramCompanyFurthest phaseStudies
frexalimabSanofiphase 311
dazodalibepruleAmgenphase 39
dapirolizumab pegolruleUCBphase 38
tegoprubartruleeledon-pharmaceuticalsphase 38
OPT101ruleop-t-llcphase 24
TNX-1500ruleTonix Pharmaceuticalsphase 11

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06972446Arthritis, Rheumatoid · United States, Canada, Czechia and more2RecruitingFeb 2027180
NCT06402513Healthy Volunteers · United States1CompletedOct 8, 202412
NCT05217472Sjogren's Syndrome · Netherlands2WithdrawnApr 15, 20220
NCT03695185Colitis, Ulcerative · United States, Canada, France and more2CompletedApr 5, 202142

How it is read

Names in the registry

  • “Ravagalimab”, 3 entries
  • “Ravagalimab 600 mg”, 1 entry
  • “Ravagalimab 300 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.